CN121517419A - 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物 - Google Patents

用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物

Info

Publication number
CN121517419A
CN121517419A CN202511808384.4A CN202511808384A CN121517419A CN 121517419 A CN121517419 A CN 121517419A CN 202511808384 A CN202511808384 A CN 202511808384A CN 121517419 A CN121517419 A CN 121517419A
Authority
CN
China
Prior art keywords
group
alkyl
compound
pharmaceutically acceptable
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511808384.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·维达尔
M·卡利法
M·马奎尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Srefor Therapy Co ltd
Original Assignee
Srefor Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Srefor Therapy Co ltd filed Critical Srefor Therapy Co ltd
Priority claimed from CN202280012928.4A external-priority patent/CN117062817A/zh
Publication of CN121517419A publication Critical patent/CN121517419A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202511808384.4A 2021-01-13 2022-01-12 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物 Pending CN121517419A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163136782P 2021-01-13 2021-01-13
US63/136,782 2021-01-13
US202163262040P 2021-10-04 2021-10-04
US63/262,040 2021-10-04
CN202280012928.4A CN117062817A (zh) 2021-01-13 2022-01-12 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物
PCT/CA2022/050038 WO2022150911A1 (en) 2021-01-13 2022-01-12 Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280012928.4A Division CN117062817A (zh) 2021-01-13 2022-01-12 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物

Publications (1)

Publication Number Publication Date
CN121517419A true CN121517419A (zh) 2026-02-13

Family

ID=82446316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202511808384.4A Pending CN121517419A (zh) 2021-01-13 2022-01-12 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物

Country Status (8)

Country Link
US (1) US20240309005A1 (https=)
EP (1) EP4277905A4 (https=)
JP (1) JP2024502178A (https=)
KR (1) KR20230136622A (https=)
CN (1) CN121517419A (https=)
AU (1) AU2022208639A1 (https=)
MX (1) MX2023008219A (https=)
WO (1) WO2022150911A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525475A (ja) * 2022-07-12 2025-08-05 スリブ セラピューティクス インコーポレイテッド Ｎ－［４－（４－［［２－（ジメチルアミノ）エチル］アミノ］－３－メチル－１Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－６－イル）－２－フルオロフェニル］－２，５－ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
WO2025072438A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827849B2 (ja) * 2011-09-20 2015-12-02 サノフイ Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
WO2015048531A1 (en) * 2013-09-26 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Inhibition of sgk1 in the treatment of heart conditions
AU2017373758B2 (en) * 2016-12-07 2021-12-16 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof

Also Published As

Publication number Publication date
WO2022150911A8 (en) 2022-09-09
CA3172186A1 (en) 2022-07-21
EP4277905A1 (en) 2023-11-22
EP4277905A4 (en) 2025-01-01
WO2022150911A1 (en) 2022-07-21
KR20230136622A (ko) 2023-09-26
US20240309005A1 (en) 2024-09-19
JP2024502178A (ja) 2024-01-17
AU2022208639A1 (en) 2023-07-20
MX2023008219A (es) 2023-08-24

Similar Documents

Publication Publication Date Title
CN113272301B (zh) 杂环类化合物、中间体、其制备方法及应用
KR101958632B1 (ko) Ａｔｒ 키나제의 억제제로서 유용한 피라진 유도체
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
EP2044051B1 (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
CN121517419A (zh) 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物
CN106573937B (zh) 作为fshr调节剂的吡唑化合物及其用途
KR20180015261A (ko) 신규한 아미노산 유도체, 이의 제조방법, 및 이를 함유한 약제 조성물
KR102470130B1 (ko) 아폽토시스 억제제
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
JPWO2019189555A1 (ja) 複素環化合物
AU2019344240B2 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
CN114599653A (zh) 作为造血祖细胞激酶1(hpk1)抑制剂的吲唑及其使用方法
JP4039574B2 (ja) チエノピリミジン化合物およびその用途
CA3172186C (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1
CN117062817A (zh) 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物
CN115785154A (zh) 杂芳环化合物及其医药用途
EP3589615B1 (en) Pyridyl derivatives as bromodomain inhibitors
WO2024015055A1 (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
CN113004252B (zh) 一种芳基并咪唑类衍生物及其用途
CN120457122A (zh) 微管蛋白聚合抑制剂
WO2022253081A1 (zh) 氧化膦衍生物及其制备方法和应用
JP2008094846A (ja) チエノピリミジン化合物およびその用途
HK1110584A (en) 2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination